SCHEMBL464730

SCHEMBL464730

CCC1CNCCO1.NS(=O)(=O)c1cccc2c1OCO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EED O75530 1/20 0.39
SLC6A2 P23975 8/20 0.37
SLC6A3 Q01959 7/20 0.37
SLC6A4 P31645 5/20 0.37
HTR2A P28223 2/20 0.37
HTR2B P41595 2/20 0.37
ADRB2 P07550 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA1A P35348 1/20 0.37
MGAM O43451 1/20 0.35
AMY1A P0DUB6 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
ADRA2C P18825 1/20 0.35
HRH1 P35367 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
HTR3A P46098 1/20 0.34
HTR1D P28221 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL464746 0.92 EED (0.38) EEDSLC6A2SLC6A3SLC6A4HTR2A
SCHEMBL464771 0.82 SSTR4 (0.38) EEDMGAMAMY1AGAASI
SCHEMBL464734 0.77 ABCG2 (0.41) PTGS1PTGS2CA2
SCHEMBL464723 0.71 MGAM (0.37) HTR2AMGAMAMY1AGAASI
SCHEMBL464731 0.70 MGAM (0.37) MGAMAMY1AGAASIMGAM2
Sulfuric Acid SCHEMBL11797708 0.68 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4HTR2AHTR2B
Sulfuric Acid SCHEMBL11797703 0.68 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4HTR2AHTR2B
SCHEMBL10664550 0.68 ACLY (0.44) PTGS1PTGS2CA2
Methylamine SCHEMBL27942975 0.68 SLC6A2 (0.45) SLC6A2SLC6A3SLC6A4HTR2AHTR2B
Methylamine SCHEMBL27804294 0.68 SLC6A2 (0.45) SLC6A2SLC6A3SLC6A4HTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
EP-1686113-B1 Inhibitors of aspartyl protease VERTEX PHARMA (US) 2011-11-23 EP disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1686113-A1 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-08-02 EP disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 EED 3568/4885SLC6A2 3374/4885SLC6A3 2330/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 EED 3568/4885SLC6A2 3374/4885SLC6A3 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.